Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.44 |
| ▸ | RHEB | Q15382 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 3/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31651607 | 1.00 | ULK1 (0.47) | ULK1GRIN1EIF4A3RHEBCYP1A2 | |
| SCHEMBL26372677 | 0.86 | ULK1 (0.48) | ULK1GRIN1EIF4A3RHEBCYP1A2 | |
| SCHEMBL9433015 | 0.84 | GRIN1 (0.66) | ULK1GRIN1EIF4A3RHEBCYP1A2 | |
| SCHEMBL30995242 | 0.84 | ALOX15 (0.52) | GRIN1EIF4A3 | |
| SCHEMBL30995243 | 0.84 | ALOX15 (0.52) | GRIN1EIF4A3 | |
| SCHEMBL24020677 | 0.82 | ULK1 (0.47) | ULK1GRIN1EIF4A3RHEBCYP1A2 | |
| SCHEMBL30310492 | 0.82 | ULK1 (0.53) | ULK1CYP1A2XDHNR4A2FLT3 | |
| SCHEMBL20494852 | 0.82 | ULK1 (0.53) | ULK1CYP1A2XDHNR4A2FLT3 | |
| SCHEMBL19331121 | 0.82 | ULK1 (0.53) | ULK1GRIN1EIF4A3RHEBCYP1A2 | |
| SCHEMBL30310352 | 0.82 | ULK1 (0.47) | ULK1GRIN1EIF4A3RHEBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11304929-B2 | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-19 | — | — | US | disclosed |
| US-20220008386-A1 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-01-13 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3596064-B1 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-03 | — | — | EP | disclosed |
| WO-2018191146-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11304929-B2 | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | PHGDH, G6PD, PHPT1 | ULK1 2875/4885GRIN1 2362/4885EIF4A3 1815/4885 |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | RHEB, KRAS, NRAS | ULK1 2667/4885GRIN1 4280/4885EIF4A3 943/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | ULK1 1355/4885GRIN1 4309/4885EIF4A3 1080/4885 |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | RHEB, GDI2, KRAS | ULK1 1980/4885GRIN1 3080/4885EIF4A3 605/4885 |
| US-20220008386-A1 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS | PHGDH, G6PD, PHPT1 | ULK1 2875/4885GRIN1 2362/4885EIF4A3 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.